JP2016502526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502526A5 JP2016502526A5 JP2015542769A JP2015542769A JP2016502526A5 JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5 JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding antibody
- composition according
- subject
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727334P | 2012-11-16 | 2012-11-16 | |
| US61/727,334 | 2012-11-16 | ||
| PCT/US2013/070042 WO2014078502A1 (en) | 2012-11-16 | 2013-11-14 | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502526A JP2016502526A (ja) | 2016-01-28 |
| JP2016502526A5 true JP2016502526A5 (enExample) | 2016-12-28 |
Family
ID=49679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542769A Pending JP2016502526A (ja) | 2012-11-16 | 2013-11-14 | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000565B2 (enExample) |
| EP (1) | EP2919811B1 (enExample) |
| JP (1) | JP2016502526A (enExample) |
| AU (1) | AU2013344796B2 (enExample) |
| CA (1) | CA2891556A1 (enExample) |
| WO (1) | WO2014078502A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180291097A1 (en) * | 2015-06-04 | 2018-10-11 | Craig Basson | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| CA2988055A1 (en) | 2015-06-04 | 2016-12-08 | Novartis Ag | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| CA2994043A1 (en) | 2015-07-31 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Antibody variants |
| JP7189017B2 (ja) * | 2015-11-24 | 2022-12-13 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 細胞培養におけるウイルスの生産 |
| KR20190032436A (ko) * | 2016-07-21 | 2019-03-27 | 노파르티스 아게 | 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20200315540A1 (en) | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| US20200207848A1 (en) * | 2017-09-13 | 2020-07-02 | Novartis Ag | Use of il-1b binding antibodies for the treatment of alcoholic hepatitis |
| FI3852617T3 (fi) * | 2018-09-20 | 2025-10-21 | Sfj Pharma X Inc | Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
| US20260015427A1 (en) | 2024-06-25 | 2026-01-15 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
| CA2722620A1 (en) | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating peripheral arterial disease |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20100054A1 (es) * | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
| CA2735939A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for improvement of beta cell function |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CN102369217A (zh) * | 2009-01-29 | 2012-03-07 | 雅培制药有限公司 | Il-1结合蛋白 |
| BRPI1011228A2 (pt) | 2009-05-29 | 2019-09-24 | Xoma Technology Ltd. | métodos para reduzir um evento cardiovascular em um indivíduo, mortalidade seguindo um evento cardiovascular em um indivíduo e restenose em um indivíduo seguindo um procedimento de revascularização, e, para tratar um evento cardiovascular em um indivíduo e hipertensão aguda em um indivíduo. |
| TW201124427A (en) * | 2009-10-15 | 2011-07-16 | Abbott Lab | IL-1 binding proteins |
| US8735546B2 (en) * | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2013049278A1 (en) * | 2011-09-30 | 2013-04-04 | Novartis Ag | USE OF IL-1 ß BINDING ANTIBODIES |
-
2013
- 2013-11-14 AU AU2013344796A patent/AU2013344796B2/en not_active Ceased
- 2013-11-14 CA CA2891556A patent/CA2891556A1/en not_active Abandoned
- 2013-11-14 EP EP13798486.0A patent/EP2919811B1/en not_active Not-in-force
- 2013-11-14 JP JP2015542769A patent/JP2016502526A/ja active Pending
- 2013-11-14 US US14/442,536 patent/US10000565B2/en active Active
- 2013-11-14 WO PCT/US2013/070042 patent/WO2014078502A1/en not_active Ceased
-
2018
- 2018-05-21 US US15/984,993 patent/US20180258166A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,341 patent/US20200148759A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,400 patent/US20210317202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| Accardi et al. | Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP5417653B2 (ja) | 抗−４−１ｂｂ抗体及び化学抗癌剤を含む癌疾患の予防及び治療用調合薬学的組成物 | |
| JP2015187125A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| KR20180018695A (ko) | 항암제 | |
| RU2471483C2 (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| CA3043700A1 (en) | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease | |
| JP2013506684A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| JP2016537380A5 (enExample) | ||
| JP2016502526A (ja) | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 | |
| Frappaz et al. | Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours | |
| KR20240090993A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| Topal et al. | Scleroderma therapy: clinical overview of current trends and future perspective | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis | |
| JP2018516931A5 (enExample) | ||
| AU2019392742A1 (en) | Anti-cancer activity of adamantane derivatives | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP2018537522A (ja) | 組合せ | |
| CA3118690A1 (en) | Use of tivozanib to treat subjects with refractory cancer | |
| CN119894507A (zh) | 嵌合抗原受体（car）t细胞辅助疗法 |